Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder

Completed · Phase 4

Conditions studied: Schizophrenia, Schizoaffective Disorder

In brief

The purposes of this study are to assess the efficacy, safety, and side effects among doses approved by the Food and Drug Administration and higher (not FDA approved) doses of olanzapine in patients with schizophrenia or schizoaffective disorder.

Key facts

Study ID
NCT00100776
Run by
Eli Lilly and Company
People needed
600
Starts
2003-09-01
Expected to finish
2005-11-01
Last updated by the study team
2007-01-26

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.